An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Isturisa

Chemical Nameosilodrostat
Dosage FormTablets (oral; 1 mg, 5 mg, 10 mg)
Drug ClassInhibitors
SystemEndocrine
CompanyRecordati Rare Disease, Inc.
Approval Year2020

Indication

  • Indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.
Last updated on 12/8/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Isturisa (osilodrostat) Prescribing Information.2020Recordati Rare Disease, Inc. Lebanon, NJ
Document TitleYearSource
Efficacy and safety of osilodrostat in patients with Cushing’s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.2020The Lancet Diabetes & Endocrinology
A phase III, multi-center, randomized, double-blind, 48 week study with an initial 12 week placebo-controlled period to evaluate the safety and efficacy of osilodrostat in patients with cushing's disease.2020Novartis